BRAF and melanoma: These features to a clinician/pathologist might include melanomas exhibiting clinical characteristics associated with BRAF mutation (summarized in Table 1), thick tumors of Breslow depth 2–4 or >4 mm with or without ulceration (i.e., stages IIB and IIC, respectively) and all patients with nodal involvement (i.e., stage III) or lymphatic progression (satellitosis or in transit metastasis).